IL2 and cancer: The enthusiasm for harnessing protein engineering and computationally modeled biologics is sharply reflected in these diverse examples of drug development, and it seems that the continuous exploration and interrogation of IL-2 as a viable target for cancer immunotherapy is poised to yield a new generation of promising therapeutic approaches expressly designed to mitigate immunologic toxicities.